CYTOAGENTS
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation also known as cytokine storm.
CYTOAGENTS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2018-01-01
Address:
Pittsburgh, Pennsylvania, United States
Country:
United States
Website Url:
http://www.cytoagents.com
Total Employee:
1+
Status:
Active
Total Funding:
10.21 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Font Awesome
Similar Organizations
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Walden Biosciences
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease.
Watchmaker Genomics
Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
Current Employees Featured
Founder
Investors List
Innovation Works
Innovation Works investment in Seed Round - CytoAgents
National Institutes of Health
National Institutes of Health investment in Grant - CytoAgents
Innovation Works
Innovation Works investment in Seed Round - CytoAgents
AlphaLab Health
AlphaLab Health investment in Seed Round - CytoAgents
Richard King Mellon Foundation
Richard King Mellon Foundation investment in Grant - CytoAgents
National Institutes of Health
National Institutes of Health investment in Grant - CytoAgents
EQx Fund
EQx Fund investment in Convertible Note - CytoAgents
Innovation Works
Innovation Works investment in Seed Round - CytoAgents
Boston Harbor Angels
Boston Harbor Angels investment in Angel Round - CytoAgents
Key Employee Changes
| Date | New article |
|---|---|
| 2022-09-07 | CytoAgents Announces Appointment of New Chief Medical Officer |
Official Site Inspections
http://www.cytoagents.com
- Host name: 219.112.62.166.host.secureserver.net
- IP address: 166.62.112.219
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "CytoAgents"
Innovative Treatments for Cytokine Release Syndrome
CytoAgents has made tremendous progress in the fight against CRS. We have successfully completed Phase 1 Human Clinical Trials and are currently conducting our Phase 1b/2a Clinical Trial to treat CRS in patients receiving …See details»
About CytoAgents
CytoAgents is focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS). There are many causes of CRS, and our mission is to …See details»
CytoAgents - Crunchbase Company Profile & Funding
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life …See details»
Our Team | Teresa Whalen - CytoAgents
As the CEO of CytoAgents, Teresa leads a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of groundbreaking …See details»
CytoAgents, Inc - LinkedIn
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine ...See details»
CytoAgents 2025 Company Profile: Valuation, Funding & Investors …
CytoAgents General Information Description. Developer of innovative pharmaceutical drugs designed to treat cytokine release syndrome. The company's drugs develop a broadly …See details»
Cytoagents, Inc. - VentureRadar
" CytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with …See details»
CytoAgents Company Profile | Management and Employees List
CytoAgents Profile and History CytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, …See details»
CytoAgents - Funding, Financials, Valuation & Investors
CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza, and other viral infectious diseases. New. Resources. Advanced Search. ... How much funding …See details»
CytoAgents | Pittsburgh, PA, USA Startup - gust.com
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment the of life-threatening symptoms associated with Cytokine Releasing Syndrome (CRS), …See details»
CytoAgents Company Profile - Office Locations, Competitors
CytoAgents is a biotechnology company that specializes in developing pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome …See details»
CytoAgents - Contacts, Employees, Board Members, Advisors
CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza, and other viral infectious diseases. ... Pricing. Log In. Log In. Experience the new Crunchbase, …See details»
CytoAgents company information, funding & investors
CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with …See details»
Cytoagents - Company Profile - Tracxn
Jan 9, 2025 CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release Syndrome in CAR T-cell TherapyBusiness Wire • Oct 17, 2023 • …See details»
CytoAgents - Overview, News & Similar companies | ZoomInfo.com
CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology PITTSBURGH--(BUSINESS WIRE)-- #CRS--CytoAgents, …See details»
CYTOAGENTS’ TERESA WHALEN SELECTED FOR COMPETITIVE EY …
Nov 8, 2021 CytoAgents is a privately held, clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening …See details»
CytoAgents - Products, Competitors, Financials, Employees, …
CytoAgents is also enrolling patients in a Phase 1b/2a clinical trial evaluating CTO1681 to treat CRS in lymphoma patients receiving CAR T-Cell Therapy. This clinical trial is being conducted …See details»
CytoAgents, Inc. | Life Sciences PA - Default Site
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with …See details»
Award - SBIR
Abstract CytoAgents is developing GP1681 (beraprost-314d) to regulate the uncontrolled inflammatory response that can result from viral infections. ... represents a severe public …See details»
Press Release Archives - CytoAgents
Mar 10, 2021 PITTSBURGH–(BUSINESS WIRE)–CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead …See details»